36
Table 15. Statin Combination Therapies
(clinical trial results)
Class
Agents Dose
Cholesterol
absorption inhibitor
Ezetimibe 10 mg/day
Bile acid
sequestrants
Colesevelam 3.75 g/day
Cholestyramine 8–16 g/day
Colestipol
Niacin Extended release 2 g/day
Fibrates Gemfibrozil 600 mg bid before meals
Fenofibrate 130 mg daily
Fenofibric acid 45–135 mg daily (delayed
release)
Omega-3 fatty acids EPA varies
EPA+DHA varies
PCSK9 inhibitors Alirocumab 150 mg subcut q2wks
Evolocumab 140 mg subcut q2wks
Residual Risk After Statins and
Lifestyle Modification
